Author

D. Alkam

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

A. Basnakian· 1 shared A. Ghaffarieh· 1 shared A. Gies· 1 shared A. Graham· 1 shared B. M. Nagalo· 1 shared C. C. Simoes· 1 shared C. Dumbauld· 1 shared C. L. Washam· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Basnakian

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

An ex vivo human precision-cut lung slice platform provides insight into SARS-CoV-2 pathogenesis and antiviral drug efficacy

X. Zhang, R. D. Pechous, P. A. Malaviarachchi, S. K. Banerjee, S. Byrum, D. Alkam, A. Ghaffarieh, R. C. Kurten, J. L. Kennedy

This paper establishes an ex vivo human precision-cut lung slice platform to study SARS-CoV-2 infection, immune responses, and drug efficacy, identifying key cytokines and viral RNA persistence as important features of COVID-19.

bioRxiv · Apr 18, 2023 · PreprintMicrobiology

In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis

Y. Zhang, M. Tesfay, K. U. Ferdous, M. Taylor, M. N. Gabere, C. C. Simoes, C. Dumbauld, O. Barro, A. Graham, C. L. Washam, D. Alkam, A. Gies, J. C. Chamcheu, S. D. Byrum, S. R. Post, , B. M. Nagalo

This study evaluates the in vivo safety and immunoactivity of Jurona virus in hepatocellular carcinoma using proteogenomic analysis, showing tumor regression and enhanced immune responses.

bioRxiv · Sep 9, 2022 · PreprintImmunology